⌘+K

Pulse Explore Communities Researchers Journals

Home Communities Explore

October 1, 2025

Figure S7 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma

Kunling Chen Huolun Feng Yujie Zhang Jingyuan Pei Yuyan Xu Xiangxu Wei Zhuohao Chen Zhoubin Feng Lei Cai Yong Li Liang Zhao Mingxin Pan

View at Publisher

Ask AI

Bookmark

Share

Key Points

CCL16 interaction with ICAM-1 normalizes tumor vasculature, enhancing treatment efficacy against hepatocellular carcinoma.
Activation of the JAK2/STAT6-IL24 axis is crucial for vascular normalization in tumor environments.
Improving immunotherapy effectiveness through vascular normalization can lead to better patient outcomes.
Macrophages play a pivotal role in mediating the effects of CCL16 on tumor vasculature.

Implication

Research shows CCL16 optimizes tumor vasculature via ICAM-1, suggesting improved immunotherapy efficacy.

Abstract

CCL16-ICAM-1 interaction activates JAK2/STAT6-IL24 axis in promoting vascular normalization.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Chen et al. (2025) studied this question.

synapsesocial.com/papers/68de68f183cbc991d0a21b09 https://doi.org/10.1158/0008-5472.30254926

View at Publisher

Ask AI

Bookmark

Share

Keep reading

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Figure S6 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
2Figure S2 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
3Figure S1 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
4Figure S8 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
5Figure S5 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025

Figure S9 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
Data from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025
Table S1 from Tumor-Derived CCL16 Normalizes Tumor Vasculature through Macrophage ICAM-1 Receptor and Enhances Immunotherapy Efficacy in Hepatocellular Carcinoma2025